Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -4.00% and closed at $1.44, with the total traded volume of 4,199.00 shares. During last trade its minimum price was $1.44 and it gained its highest price of $1.50 has a total of 40.91 million outstanding shares.
Earth Science Tech Inc (ETST) on March 6, 2017 announced that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.
At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.
The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) showing dropped of -10.20% and closed at $0.880, after gaining total volume of 1.76M shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at -6.02 points and has total market capitalization of $113.29 million and a total of 135.31 million outstanding shares.
OWC Pharmaceutical Research Corp (OWCP) on March 21, 2017 announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis.
In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue. The recent results are highly promising, showing significant reduction of several inflammation markers specific to psoriasis.
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC’s scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions.
Dr. Yehuda Baruch, the Company’s Chief Science Officer and Director of Research and Regulatory Affairs, commented, “As a practicing physician and a scientist who has been treating patients with cannabis for medical purposes for more than two decades, I am truly excited by our success to date and, more importantly, I am thrilled to be part of a professional scientific study on humans that should actually validate what I have believed and experienced for years – Cannabis helps treat a multitude of health conditions.”
Dr. Sharon Rozenblat, PhD – Biochemistry, a member of OWC Scientific Advisory Board added, “After many years of being actively involved in research and development of innovative dermatological treatments and being exposed to the many scientific articles and peer reviewed works and publications regarding skin conditions and diseases, I would like to emphasize my personal belief that OWC’s psoriasis results have been indeed unique in the most positive sense.” Dr. Rozenblat continued by stating, “While there is still scientific work to be done, as a scientist I am extremely excited to be part of OWC’s study that appears to become a highly possible breakthrough that can improve the life of psoriasis patients and, possibly, other skin conditions.”
Kush Bottles Inc (OTCMKTS:KSHB) increased 7.95% closed at $2.60 and traded with total volume of 128,215.00 shares, while the average trading remained 151,246.00 shares. During last trade its minimum price was $2.45 and it gained the highest price of $2.65. Its market capitalization was $129.31 million.
Kush Bottles Inc (KSHB) on March 23, 2017 announced that on July 1, 2017, it will move its corporate headquarters and California fulfillment center to a larger, more centrally located facility in Garden Grove, CA. The new building features greater warehouse space to allow for increased inventory, as well as additional floor space to support new services for the company’s growing customer base.
A recent report from the World Bank stated that California just surpassed the nation of France to become the world’s sixth largest economy, only outpaced by the US (as a whole), China, Japan, Germany, and the UK.
According to an article in Business Insider, the size of the cannabis market in California could reach $4.27 billion in 2018, and could grow to $6.45 billion by 2020.
Bolstering this projected growth are two recent voter-approved initiatives: Proposition 64, the “Adult Use of Marijuana Act” legalized the purchase of cannabis for adults 21 and older in California; and Measure M, which was recently passed in Los Angeles and will allow the nation’s second largest city to repeal a current ban on medical marijuana dispensaries. The measure also allows the city council to create new rules in order to facilitate a safe and well-regulated legal cannabis industry.
“Kush Bottles thrives in regulated cannabis markets, where strict rules require the use of certified, child resistant packaging,” said Nick Kovacevich, CEO of Kush Bottles, Inc. “We are excited about the passage of Measure M, which will allow newly established and existing medical marijuana facilities to legally operate in Los Angeles under new rules to create a safe and well-regulated market.”